In Vitro Chromosomal Aberration Test for Medical Devices: Principles, Methods, and Regulatory Requir

The in vitro mammalian chromosomal aberration test is a core genotoxicity assay used to determine whether extracts from medical devices can induce structural or numerical chromosome damage in cultured mammalian cells. Performed in accordance with ISO 10993-3, ISO 10993-12, and OECD Test Guideline 473, this test is an essential component of the biological evaluation program required for regulatory submissions across global markets. This article explains the test principle, sample preparation, methodology, data interpretation, and typical applications for medical device manufacturers.

Technical Overview

The in vitro mammalian chromosomal aberration test is a genotoxicity assay designed to detect substances that cause damage to chromosomes, expressed as structural aberrations (breaks, exchanges, rings, dicentrics) or numerical aberrations (polyploidy, endoreduplication) in dividing mammalian cells. Within medical device biological evaluation, the test is mandated by ISO 10993-3 (Biological evaluation of medical devices — Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity) whenever genotoxicity assessment is triggered by the risk-based evaluation described in ISO 10993-1. The technical conduct of the assay follows OECD Test Guideline 473 (In Vitro Mammalian Chromosomal Aberration Test), which defines cell systems, dose selection, metabolic activation, scoring criteria, and result interpretation.

In this assay, cultured mammalian cells are exposed to extracts of the medical device in both the absence and presence of an exogenous metabolic activation system (S9 mix). After treatment, cells are arrested at metaphase, swollen hypotonically, fixed, stained, and examined microscopically. Agents that significantly increase the frequency of metaphase cells with chromosomal aberrations are considered clastogenic, while agents that increase polyploidy or endoreduplication may indicate disruption of cell-cycle or spindle apparatus function. Because chromosome damage is strongly correlated with mutagenic and carcinogenic events, a positive finding typically requires follow-up evaluation, such as an in vivo micronucleus test conducted under OECD Test Guideline 474.

• ISO 10993-1: Evaluation and testing within a risk management process
• ISO 10993-3: Tests for genotoxicity, carcinogenicity and reproductive toxicity
• ISO 10993-12: Sample preparation and reference materials
• ISO 10993-33: Supplementary guidance on genotoxicity test strategies
• OECD Test Guideline 473: In Vitro Mammalian Chromosomal Aberration Test
• GB/T 16886.3 and GB/T 16886.12: Chinese national standards harmonized with the ISO 10993 series

Testing Samples

Device Contact Categories

Devices spanning all ISO 10993-1 contact categories can be evaluated, including surface-contacting devices (skin, mucosal membranes, breached surfaces), external communicating devices (indwelling catheters, tubing sets, blood-contacting devices), and implant devices (orthopedic, dental, cardiovascular, and absorbable implants). Genotoxicity testing is most frequently triggered for devices with prolonged contact exceeding 24 hours, permanent-contact implants, blood-contacting products, resorbable or biodegradable materials, and devices whose chemical characterization has identified potentially genotoxic leachables.

Sample Preparation and Extraction

Test articles are prepared as extracts according to ISO 10993-12 using both a polar vehicle (such as physiological saline or serum-supplemented culture medium) and a non-polar vehicle (such as sesame oil or cottonseed oil), because device leachables may be hydrophilic or lipophilic and a single vehicle cannot adequately recover both classes. Standardized extraction ratios are based on material geometry, for example 6 cm²/mL for materials thinner than 0.5 mm, 3 cm²/mL for materials between 0.5 mm and 1.0 mm, and mass-based ratios such as 0.1 g/mL to 0.2 g/mL for porous or irregularly shaped items. The preferred extraction condition is 37 °C for 24 hours to simulate physiological exposure; accelerated or exaggerated conditions such as 50 °C for 72 hours or 70 °C for 24 hours may be used when justified by material stability. All extraction steps are performed aseptically, and extracts are tested promptly after preparation.

Representative Product Types

• Intravenous catheters, infusion sets, syringes, and blood tubing
• Hemodialyzers, blood oxygenators, and extracorporeal circuit components
• Orthopedic implants, bone cements, and dental materials
• Cardiovascular stents, grafts, pacemaker leads, and delivery systems
• Wound dressings, hydrogels, absorbable hemostats, and tissue adhesives
• Resorbable scaffolds and controlled-release depots
• Drug-device combination products and device leachables or degradation products

Testing Items

The assay quantifies the percentage of metaphase cells carrying chromosomal aberrations and records complementary cytogenetic and cytotoxicity endpoints:

• Chromatid-type aberrations: chromatid gaps, breaks, acentric fragments, and exchanges such as triradials and quadriradials
• Chromosome-type aberrations: chromosome gaps, breaks, acentric fragments, dicentrics, rings, and translocations
• Numerical aberrations: polyploid metaphases and endoreduplicated cells
• Cytotoxicity parameters: mitotic index, relative cell growth inhibition, and changes in cell morphology
• Extract characterization: appearance, pH, and osmolality recorded to rule out culture artifacts

Chromatid and chromosome gaps are recorded and reported separately because they are generally not counted as structural aberrations in the final evaluation, consistent with OECD Test Guideline 473 scoring conventions.

Testing Methods

Test Systems

Commonly used cell systems include Chinese hamster lung fibroblasts (CHL/IU), Chinese hamster ovary (CHO) cells, V79 cells, and primary human peripheral blood lymphocytes. These cell lines possess stable chromosome complements, rapid proliferation, and low spontaneous aberration backgrounds, making them suitable for metaphase analysis.

Dose Selection and Treatment Design

Extracts are tested at multiple concentrations, typically starting from the neat (100%) extract and proceeding through serial dilutions, for example 50%, 25%, and 12.5%. The highest analyzable concentration is limited either by cytotoxicity, with the top dose targeting approximately 50% reduction in cell growth or mitotic index, or by the maximum achievable extract concentration when no cytotoxicity occurs. Cells are treated under multiple exposure schemes: a short-term treatment of about 6 hours with metabolic activation, a short-term treatment without activation followed by recovery, and a continuous treatment of approximately 24 hours without activation. Metaphase arrest is achieved using colcemid or colchicine during the final 2 to 3 hours, and cells are harvested at roughly 1.5 normal cell cycles after treatment initiation.

Slide Preparation and Microscopic Scoring

Harvested cells undergo hypotonic treatment with potassium chloride, fixation with methanol and acetic acid, and staining with Giemsa. Well-spread metaphases are scored by trained analysts under blinded conditions, with at least 200 metaphases analyzed per concentration across duplicate cultures. Aberrations are classified by type and scored against historical control distributions, and polyploid and endoreduplicated cells are enumerated separately.

Control Design

• Negative control: extraction vehicle processed identically to the test article to confirm background aberration rates
• Positive control without metabolic activation: mitomycin C or methyl methanesulfonate
• Positive control with metabolic activation: cyclophosphamide or benzo[a]pyrene
• Historical control database: maintained by the laboratory to verify assay sensitivity and scoring consistency

Data Analysis and Interpretation

Statistical evaluation is performed using Fisher's exact test or chi-square analysis with trend assessment. A test article is considered positive when it produces a reproducible, statistically significant increase in aberrant cells relative to the vehicle control, exceeding the laboratory's historical control range, ideally with a dose-related response. A negative result is valid only when the vehicle control falls within the historical range, positive controls respond appropriately, and adequate cytotoxicity or maximum exposure was achieved at the top dose. Biological relevance is weighed alongside statistical significance in the final judgment.

Applications

Chromosomal aberration data are integral to biological evaluation reports and regulatory dossiers, demonstrating that device leachables do not pose unacceptable genotoxic risk. Under the ISO 10993-3 test strategy, genotoxicity evaluation typically combines a bacterial reverse mutation test (OECD Test Guideline 471) for gene mutations with the in vitro chromosomal aberration test or in vitro micronucleus test (OECD Test Guideline 487) for chromosomal damage, ensuring coverage of the two major classes of genetic damage.

• Registration dossiers submitted to national medical device authorities, including China NMPA submissions aligned with the GB/T 16886 series
• Premarket notification and approval submissions to the U.S. FDA
• Technical documentation supporting conformity assessment under the EU MDR
• Risk management files demonstrating compliance with ISO 10993-1 and ISO 14971
• Research and development screening of new materials, additives, colorants, adhesives, sterilization processes, and packaging interactions
• Change control evaluations when materials, suppliers, or manufacturing processes are modified
• Justification for waiving or triggering in vivo genotoxicity follow-up studies

Accredited third-party laboratories routinely perform this assay under Good Laboratory Practice principles, providing manufacturers with data packages that satisfy the expectations of regulators across multiple jurisdictions without the need to name any specific service provider.

FAQ

Question: When is a chromosomal aberration test required for a medical device?

Answer: The requirement is determined by the risk-based framework of ISO 10993-1. Testing is commonly triggered for devices with prolonged or permanent patient contact, blood-contacting devices, implants, resorbable materials, and devices for which chemical characterization under ISO 10993-18 has identified leachables of potential genotoxic concern.

Question: Why must both polar and non-polar extracts be tested?

Answer: Device leachables vary widely in solubility. A polar vehicle recovers hydrophilic substances while a non-polar vehicle recovers lipophilic substances, and ISO 10993-3 requires evaluation using both extraction vehicles to ensure comprehensive coverage of the extractable chemical profile.

Question: What is S9 metabolic activation and why is it included?

Answer: S9 mix is a liver post-mitochondrial fraction from induced rats supplemented with cofactors. It simulates mammalian metabolism and enables detection of pro-mutagens that become DNA-damaging only after biotransformation, which cultured cells cannot perform on their own.

Question: How does this test differ from the Ames test and the micronucleus test?

Answer: The Ames test detects point mutations in bacteria, the chromosomal aberration test identifies structural and numerical chromosome damage in mammalian cells in vitro, and the micronucleus test detects chromosome fragments or whole chromosomes lagging during cell division and can be performed in vitro or in vivo. The standards recommend a battery that addresses both gene mutation and chromosomal damage endpoints.

Question: How much sample material is needed for testing?

Answer: The required quantity depends on the device geometry, thickness, and the standardized extraction ratios of ISO 10993-12. In general, sufficient material must be provided to generate the required extract volumes for multiple dose levels in two vehicles, and the testing laboratory will specify exact quantities during study planning.

Question: What makes a study valid and the result conclusive?

Answer: A valid study requires vehicle control aberration rates within the historical control range, clear positive responses from positive control chemicals, an adequate cytotoxicity or exposure gradient at the highest dose, and a sufficient number of analysable metaphases. A positive conclusion requires a reproducible, statistically and biologically significant increase in aberrations, while a negative conclusion confirms the absence of clastogenic activity under the tested conditions.

Question: What follow-up is needed if the result is positive?

Answer: A positive in vitro finding typically prompts a weight-of-evidence review of chemical characterization data and may require an in vivo micronucleus study under OECD Test Guideline 474, together with toxicological risk assessment to determine whether patient exposure levels present a genuine safety concern.